Merck & Co., Inc. (LON:MRK)

Market Cap	199.50B -3.6%
Revenue (ttm)	47.79B +1.7%
Net Income	14.16B +56.7%
EPS	5.62 +58.1%
Shares Out	n/a
PE Ratio	14.09
Forward PE	21.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,002
Average Volume	21,215
Open	46.50
Previous Close	46.50
Day's Range	46.50 - 46.50
52-Week Range	42.00 - 63.00
Beta	0.67
RSI	61.70
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Specialty Retail
• Sector: Consumer Discretionary
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD